Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | PAM | P19021 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28797963 | 0.86 | ALDH1A1 (0.68) | ALDH1A1MAPK1L3MBTL1AKR1B1TDP1 | |
| SCHEMBL3727812 | 0.85 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL28662041 | 0.83 | TDP1 (0.54) | ALDH1A1MAPK1L3MBTL1AKR1B1TDP1 | |
| SCHEMBL10627434 | 0.82 | AKR1B1 (0.61) | ALDH1A1MAPK1L3MBTL1AKR1B1TDP1 | |
| SCHEMBL9317809 | 0.81 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1TDP1PAM | |
| SCHEMBL26068711 | 0.81 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1TDP1PAM | |
| SCHEMBL10716907 | 0.81 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1TDP1PAM | |
| SCHEMBL18556313 | 0.81 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1TDP1PAM | |
| SCHEMBL20126456 | 0.81 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1TDP1PAM | |
| SCHEMBL361779 | 0.81 | ALDH1A1 (1.00) | ALDH1A1MAPK1L3MBTL1AKR1B1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110234515-A | recording material and recording sheet | 日本曹达株式会社 | 2019-09-13 | — | — | CN | disclosed |
| CN-109641472-A | Recording materials and recording sheet | 日本曹达株式会社 | 2019-04-16 | — | — | CN | disclosed |
| CN-105330630-B | Benzofuran compounds and its preparation method and application | 上海交通大学 | 2018-04-17 | — | — | CN | disclosed |
| CN-107848974-A | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2018-03-27 | — | — | CN | disclosed |
| WO-2013083991-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-06-13 | — | — | WO | disclosed |
| WO-2004096811-A1 | PDE9 INHIBITORS FOR TREATING TYPE 2 DIABETES, METABOKIC SYNDROME, AND CARDIOVASCULAR DISEASE | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| US-5508433-A | Derivatives of perhydroisoindole and preparation thereof | RHONE-POULENC RORER S.A. (FR) | 1996-04-16 | — | — | US | disclosed |
| US-5451601-A | Perhydroisoindole derivatives and pharmaceutical compositions containing them | RHONE-POULENC RORER S.A. (FR) | 1995-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PDE9A, PDE2A, PDE12 | ALDH1A1 474/4885MAPK1 257/4885L3MBTL1 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.